Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

WWTR1 (WW domain containing transcription regulator 1)

Abstract

Abstract WWTR1 (also called TAZ in publications. Therefore, TAZ is used in the following description) is a WW domaing-containing transcriptional coactivator, which was first identified as a 14-3-3 binding protein. TAZ is the downstream component in the Hippo pathway, and also has been found to interact with different pathways, such as Wnt, TGFbeta, etc. TAZ is involved in mesenchymal stem cell differentiation as well as tumorigenesis. High level of TAZ has been found in different cancers, such as breast cancer, colon cancer, lung cancer, etc.

Identity

Other namesTAZ
HGNC (Hugo) WWTR1
LocusID (NCBI) 25937
Location 3q25.1
Location_base_pair Starts at 149235022 and ends at 149421060 bp from pter ( according to hg19-Feb_2009)  [Mapping]
Local_order TM4SF4-WWTR1-COMMD2-ANKUB1.

DNA/RNA

Description TAZ maps to NC_000003.12, in the region between 149235022 to 149454501 and spans 220 kilobases. TAZ has 7 exons, ranging in size from 112 bp to 3754 bp.
Transcription The mRNA transcript spans 5135 bp with 1202 bp open reading frame.

Protein

 
  TAZ structure domain. TB: TEAD binding domain; WW: WW domain; TA: Transactivation domain, which contains a Gln-rich region (194-241 aa) and Coiled-coil region (225-259 aa); PDZB: PDZ-binding domain; S89-LATS phosphorylation site.
Description TAZ is a downstream transcriptional coactivator in the Hippo pathway (Kanai et al., 2000; Lei et al., 2008; Hong and Guan, 2012). TAZ has one WW domain which allows its interaction with PPxY motif-containing proteins such as LATS kinases in the Hippo pathway as well as other transcription factors (TFs). Its N-termini contains a Tead-binding (TB) domain, through which TAZ can bind to TEAD, which is a well-known TF involved in cell proliferation and anti-apoptosis. In its C-termini, there is a Transcriptional Activation (TA) domain which contains a Gln-rich region (amino acid (aa.) 194-241) and Coiled-coil region (aa. 225-259). From 394 to aa. 400 of TAZ, there is a PDZ-binding domain, which has been found important for transcriptional coactivating function of TAZ (Wang et al., 2009; Liu et al., 2011).
Expression TAZ is expressed in various tissues, and high expression of TAZ has been found in thyroid, kidney, heart, placenta and lung.
Localisation TAZ localizes in both cytoplasm and nucleus. Normally, in the nucleus, TAZ can possess its transcription-activating function and help initiate target genes' expressions through binding with related transcriptional factors. And the localization of TAZ can be regulated by cell-cell contact. Once cells get confluent (high cell-cell contact), the Hippo pathway will be activated (Zhao et al., 2011). As a result, TAZ will be phosphorylated on S89, initiating its binding with 14-3-3 (Lei et al., 2008; Zhao et al., 2008), which will anchor TAZ in the cytoplasm. Besides, the interaction with some proteins, such as AMOT and ZO-1, can also localize TAZ to cell membrane (Chan et al., 2011; Remue et al., 2010).
Function TAZ functions as an oncogene. Over-expression of TAZ induces increased cell proliferation, epithelial-mesenchymal transition (EMT), cell migration and transformation (Chan et al., 2009; Lai et al., 2011). In addition, enhanced levels of TAZ causes drug resistance by activating CTGF and Cyr61 (Lai et al., 2011).
TAZ is also involved in mesenchymal stem cell differentiation. TAZ can activate TF RUNX2 to induce osteoblast differentiation, while TAZ binds and inhibits PPARG TF, which further blocks adipocyte differentiation. Besides, TAZ also regulates myoblast differentiation by enhancing TF MyoD-dependent myogenic gene expression (Hong et al., 2005; Jung et al., 2009; Cho HH et al., 2010).
TAZ relates to tissue homeostasis and development as well. TAZ knockout mice develop Polycystic Kidney Disease (PKD) and emphysema, suggesting an important role of TAZ in renal and lung development (Liu et al., 2011).
TAZ also plays a role in mechanotransduction. Extracellular matrix stiffness or confined adhesiveness can cause TAZ retention in nuclear, which, therefore contributes to cell proliferation, mesenchymal stem cell differentiation as well as cancer malignant progression (Dupont et al., 2011).
Homology TAZ gene is conserved across species. Homologous proteins have been found in chimpanzee, dog, cow, mouse, rate, chicken and zebrafish.

Mutations

Note TAZ has a missense mutation (F299V), which was detected at 7% and 10% in primary mammary tumor and xenograft respectively, as well as 28% mutant allele frequency in metastatic breast cancers (Ding et al., 2010).

Implicated in

Entity Non-small cell lung cancer
Note High level of TAZ has been found in different non-small cell lung cancer (NSCLC) cell lines. TAZ overexpression in immortalized non-tumorigenic lung epithelial cells causes increased cell proliferation and transformation, whereas TAZ knockdown in NSCLC cells significantly reduces tumor cell proliferation and tumor growth in nude mice (Zhou et al., 2011). Significantly, TAZ expression was found associated with lung adenocarcinoma, metastasis, poorer differentiation and poor prognosis (Xie et al., 2012). Lung cancer patients with negative TAZ expression have prolonged overall survival (Lau et al., 2014).
  
Entity Colorectal cancer
Note High levels of TAZ mRNA are significantly correlated with shorter survival in colorectal cancer patients. This was due to the increased levels of TAZ downstream target genes CTGF and AXL, which are involved in colorectal cancer development (Yuen et al., 2013).
  
Entity Breast cancer
Note TAZ has been found correlated with breast cancers. The breast cancer cell lines have high expression of TAZ and 20% of breast cancer samples have TAZ overexpression (Chan et al., 2009). TAZ causes increased cell migration through activation of BMP4, and resistance to chemotherapeutic drug Taxol through downstream Cyr61 and CTGF (Lai et al., 2011; Lai and Yang, 2013). TAZ can also cause increased cell proliferation and tumorigenesis by activating KLF5 through inhibition of KLF5 degradation (Zhao et al., 2012). Also, TAZ has been suggested to play a role in breast cancer stem cell self-renewal and tumor-initiation capabilities (Cordenonsi et al., 2011; Bartucci et al., 2014). Moreover, TAZ is also found amplified in 44% basal-like and 30% luminal breast cancer (Skibinski et al., 2014).
  
Entity Tongue squamous cell carcinoma (TSCC)
Note TSCC cells and specimens have significantly higher expression of TAZ than those in non-cancerous cells and normal tongue mucosa. Overexpression of TAZ in TSCC was significantly associated with tumor size, clinical stage and reduced overall and disease-free survival (Wei et al., 2013).
  
Entity Polycystic kidney disease (PKD)
Note TAZ knockout mice develop PKD during development. NEK1 kinase can phosphorylate TAZ, which can disable TAZ's role in promoting the degradation of PC2, a protein involved in ciliogenesis. The proper balance of NEK1 and TAZ will help keep a good level of PC2, which will protect kidney from PKD (Tian et al., 2007; Yim et al., 2011).
  
Entity Holt-Oram syndrome
Note TAZ can interact with and activate transcription factor TBX5, which is essential in cardiac and limb development. In Holt-Oram syndrome, TBX5 has a truncated mutation, which will lose its interaction with TAZ and therefore, fail to activate genes involved in cardiac and limb development (Murakami et al., 2005).
  

Other Solid tumors implicated (Data extracted from papers in the Atlas)

Solid Tumors AmeloblastomID5945

External links

Nomenclature
HGNC (Hugo)WWTR1   24042
Cards
AtlasWWTR1ID44545ch3q25
Entrez_Gene (NCBI)WWTR1  25937  WW domain containing transcription regulator 1
GeneCards (Weizmann)WWTR1
Ensembl (Hinxton)ENSG00000018408 [Gene_View]  chr3:149235022-149421060 [Contig_View]  WWTR1 [Vega]
ICGC DataPortalENSG00000018408
cBioPortalWWTR1
AceView (NCBI)WWTR1
Genatlas (Paris)WWTR1
WikiGenes25937
SOURCE (Princeton)NM_001168278 NM_001168280 NM_015472
Genomic and cartography
GoldenPath (UCSC)WWTR1  -  3q25.1   chr3:149235022-149421060 -  3q23-q24   [Description]    (hg19-Feb_2009)
EnsemblWWTR1 - 3q23-q24 [CytoView]
Mapping of homologs : NCBIWWTR1 [Mapview]
OMIM607392   
Gene and transcription
Genbank (Entrez)AJ299431 AK022036 AK025216 AK127620 AK130514
RefSeq transcript (Entrez)NM_001168278 NM_001168280 NM_015472
RefSeq genomic (Entrez)AC_000135 NC_000003 NC_018914 NT_005612 NW_001838884 NW_004929311
Consensus coding sequences : CCDS (NCBI)WWTR1
Cluster EST : UnigeneHs.477921 [ NCBI ]
CGAP (NCI)Hs.477921
Alternative Splicing : Fast-db (Paris)GSHG0022144
Alternative Splicing GalleryENSG00000018408
Gene ExpressionWWTR1 [ NCBI-GEO ]     WWTR1 [ SEEK ]   WWTR1 [ MEM ]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9GZV5 (Uniprot)
NextProtQ9GZV5  [Medical]
With graphics : InterProQ9GZV5
Splice isoforms : SwissVarQ9GZV5 (Swissvar)
Domaine pattern : Prosite (Expaxy)WW_DOMAIN_1 (PS01159)    WW_DOMAIN_2 (PS50020)   
Domains : Interpro (EBI)WW_dom [organisation]  
Related proteins : CluSTrQ9GZV5
Domain families : Pfam (Sanger)WW (PF00397)   
Domain families : Pfam (NCBI)pfam00397   
Domain families : Smart (EMBL)WW (SM00456)  
DMDM Disease mutations25937
Blocks (Seattle)Q9GZV5
Human Protein AtlasENSG00000018408 [gene] [tissue] [antibody] [cell] [cancer]
Peptide AtlasQ9GZV5
HPRD09580
IPIIPI00180266   IPI00945652   IPI00947216   IPI00945474   IPI00947373   IPI00946549   IPI00945049   IPI00946719   
Protein Interaction databases
DIP (DOE-UCLA)Q9GZV5
IntAct (EBI)Q9GZV5
FunCoupENSG00000018408
BioGRIDWWTR1
InParanoidQ9GZV5
Interologous Interaction database Q9GZV5
IntegromeDBWWTR1
STRING (EMBL)WWTR1
Ontologies - Pathways
Ontology : AmiGOnegative regulation of transcription from RNA polymerase II promoter  osteoblast differentiation  negative regulation of protein phosphorylation  transcription coactivator activity  transcription coactivator activity  transcription corepressor activity  protein binding  nucleus  nucleus  nucleoplasm  transcription factor complex  nucleolus  cytoplasm  cytosol  transcription, DNA-templated  regulation of transcription, DNA-templated  transcription initiation from RNA polymerase II promoter  negative regulation of protein kinase activity  transforming growth factor beta receptor signaling pathway  positive regulation of cell proliferation  gene expression  positive regulation of epithelial to mesenchymal transition  stem cell division  glomerulus development  hippo signaling  hippo signaling  negative regulation of catenin import into nucleus  protein homodimerization activity  negative regulation of fat cell differentiation  positive regulation of transcription from RNA polymerase II promoter  cilium morphogenesis  regulation of SMAD protein import into nucleus  negative regulation of canonical Wnt signaling pathway  
Ontology : EGO-EBInegative regulation of transcription from RNA polymerase II promoter  osteoblast differentiation  negative regulation of protein phosphorylation  transcription coactivator activity  transcription coactivator activity  transcription corepressor activity  protein binding  nucleus  nucleus  nucleoplasm  transcription factor complex  nucleolus  cytoplasm  cytosol  transcription, DNA-templated  regulation of transcription, DNA-templated  transcription initiation from RNA polymerase II promoter  negative regulation of protein kinase activity  transforming growth factor beta receptor signaling pathway  positive regulation of cell proliferation  gene expression  positive regulation of epithelial to mesenchymal transition  stem cell division  glomerulus development  hippo signaling  hippo signaling  negative regulation of catenin import into nucleus  protein homodimerization activity  negative regulation of fat cell differentiation  positive regulation of transcription from RNA polymerase II promoter  cilium morphogenesis  regulation of SMAD protein import into nucleus  negative regulation of canonical Wnt signaling pathway  
Pathways : KEGGHippo signaling pathway   
Protein Interaction DatabaseWWTR1
Wikipedia pathwaysWWTR1
Gene fusion - rearrangments
Rearrangement : TICdbWWTR1 [3q25.1]  -  CAMTA1 [8p11.23]
Polymorphisms : SNP, mutations, diseases
SNP Single Nucleotide Polymorphism (NCBI)WWTR1
snp3D : Map Gene to Disease25937
SNP (GeneSNP Utah)WWTR1
SNP : HGBaseWWTR1
Genetic variants : HAPMAPWWTR1
Exome VariantWWTR1
1000_GenomesWWTR1 
ICGC programENSG00000018408 
Cancer Gene: CensusWWTR1 
Somatic Mutations in Cancer : COSMICWWTR1 
CONAN: Copy Number AnalysisWWTR1 
Mutations and Diseases : HGMDWWTR1
Genomic VariantsWWTR1  WWTR1 [DGVbeta]
dbVarWWTR1
ClinVarWWTR1
Pred. of missensesPolyPhen-2  SIFT(SG)  SIFT(JCVI)  Align-GVGD  MutAssessor  Mutanalyser  
Pred. splicesGeneSplicer  Human Splicing Finder  MaxEntScan  
Diseases
OMIM607392   
MedgenWWTR1
GENETestsWWTR1
Disease Genetic AssociationWWTR1
Huge Navigator WWTR1 [HugePedia]  WWTR1 [HugeCancerGEM]
General knowledge
Homologs : HomoloGeneWWTR1
Homology/Alignments : Family Browser (UCSC)WWTR1
Phylogenetic Trees/Animal Genes : TreeFamWWTR1
Chemical/Protein Interactions : CTD25937
Chemical/Pharm GKB GenePA134899667
Clinical trialWWTR1
Cancer Resource (Charite)ENSG00000018408
Other databases
Other databaseCancer Genetics Web
Probes
Litterature
PubMed58 Pubmed reference(s) in Entrez
CoreMineWWTR1
iHOPWWTR1
OncoSearchWWTR1

Bibliography

TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins.
Kanai F, Marignani PA, Sarbassova D, Yagi R, Hall RA, Donowitz M, Hisaminato A, Fujiwara T, Ito Y, Cantley LC, Yaffe MB.
EMBO J. 2000 Dec 15;19(24):6778-91.
PMID 11118213
 
TAZ, a transcriptional modulator of mesenchymal stem cell differentiation.
Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB.
Science. 2005 Aug 12;309(5737):1074-8.
PMID 16099986
 
A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome.
Murakami M, Nakagawa M, Olson EN, Nakagawa O.
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18034-9. Epub 2005 Dec 6.
PMID 16332960
 
TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex.
Tian Y, Kolb R, Hong JH, Carroll J, Li D, You J, Bronson R, Yaffe MB, Zhou J, Benjamin T.
Mol Cell Biol. 2007 Sep;27(18):6383-95. Epub 2007 Jul 16.
PMID 17636028
 
TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway.
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL.
Mol Cell Biol. 2008 Apr;28(7):2426-36. doi: 10.1128/MCB.01874-07. Epub 2008 Jan 28.
PMID 18227151
 
The Hippo-YAP pathway: new connections between regulation of organ size and cancer.
Zhao B, Lei QY, Guan KL.
Curr Opin Cell Biol. 2008 Dec;20(6):638-46. doi: 10.1016/j.ceb.2008.10.001. Epub 2008 Nov 18. (REVIEW)
PMID 18955139
 
TEADs mediate nuclear retention of TAZ to promote oncogenic transformation.
Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W.
J Biol Chem. 2009 May 22;284(21):14347-58. doi: 10.1074/jbc.M901568200. Epub 2009 Mar 26.
PMID 19324876
 
Augmentation of PPARgamma-TAZ interaction contributes to the anti-adipogenic activity of KR62980.
Jung H, Lee MS, Jang EJ, Ahn JH, Kang NS, Yoo SE, Bae MA, Hong JH, Hwang ES.
Biochem Pharmacol. 2009 Nov 15;78(10):1323-9. doi: 10.1016/j.bcp.2009.07.001. Epub 2009 Jul 8.
PMID 19591806
 
YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease.
Wang K, Degerny C, Xu M, Yang XJ.
Biochem Cell Biol. 2009 Feb;87(1):77-91. doi: 10.1139/O08-114. (REVIEW)
PMID 19234525
 
NF-kappaB activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression.
Cho HH, Shin KK, Kim YJ, Song JS, Kim JM, Bae YC, Kim CD, Jung JS.
J Cell Physiol. 2010 Apr;223(1):168-77. doi: 10.1002/jcp.22024.
PMID 20049872
 
Genome remodelling in a basal-like breast cancer metastasis and xenograft.
Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin L, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF, Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS, Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du F, Hawkins AE, O'Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson DM Jr, Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson M, Ley TJ, Wilson RK, Mardis ER.
Nature. 2010 Apr 15;464(7291):999-1005. doi: 10.1038/nature08989.
PMID 20393555
 
TAZ interacts with zonula occludens-1 and -2 proteins in a PDZ-1 dependent manner.
Remue E, Meerschaert K, Oka T, Boucherie C, Vandekerckhove J, Sudol M, Gettemans J.
FEBS Lett. 2010 Oct 8;584(19):4175-80. doi: 10.1016/j.febslet.2010.09.020. Epub 2010 Sep 18.
PMID 20850437
 
Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W.
J Biol Chem. 2011 Mar 4;286(9):7018-26. doi: 10.1074/jbc.C110.212621. Epub 2011 Jan 11.
PMID 21224387
 
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells.
Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S, Piccolo S.
Cell. 2011 Nov 11;147(4):759-72. doi: 10.1016/j.cell.2011.09.048.
PMID 22078877
 
Role of YAP/TAZ in mechanotransduction.
Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, Elvassore N, Piccolo S.
Nature. 2011 Jun 8;474(7350):179-83. doi: 10.1038/nature10137.
PMID 21654799
 
Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF.
Lai D, Ho KC, Hao Y, Yang X.
Cancer Res. 2011 Apr 1;71(7):2728-38. doi: 10.1158/0008-5472.CAN-10-2711. Epub 2011 Feb 24.
PMID 21349946
 
Regulation and function of the TAZ transcription co-activator.
Liu C, Huang W, Lei Q.
Int J Biochem Mol Biol. 2011;2(3):247-56. Epub 2011 Jul 20.
PMID 22003437
 
Nek1 and TAZ interact to maintain normal levels of polycystin 2.
Yim H, Sung CK, You J, Tian Y, Benjamin T.
J Am Soc Nephrol. 2011 May;22(5):832-7. doi: 10.1681/ASN.2010090992. Epub 2011 Apr 7.
PMID 21474562
 
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal.
Zhao B, Tumaneng K, Guan KL.
Nat Cell Biol. 2011 Aug 1;13(8):877-83. doi: 10.1038/ncb2303. (REVIEW)
PMID 21808241
 
TAZ is a novel oncogene in non-small cell lung cancer.
Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X.
Oncogene. 2011 May 5;30(18):2181-6. doi: 10.1038/onc.2010.606. Epub 2011 Jan 24.
PMID 21258416
 
The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway.
Hong W, Guan KL.
Semin Cell Dev Biol. 2012 Sep;23(7):785-93. doi: 10.1016/j.semcdb.2012.05.004. Epub 2012 May 29. (REVIEW)
PMID 22659496
 
Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu ZH, Xu F, Zhao HY.
J Thorac Oncol. 2012 May;7(5):799-807. doi: 10.1097/JTO.0b013e318248240b.
PMID 22481233
 
TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis.
Zhao D, Zhi X, Zhou Z, Chen C.
Carcinogenesis. 2012 Jan;33(1):59-67. doi: 10.1093/carcin/bgr242. Epub 2011 Oct 31.
PMID 22045023
 
BMP4 is a novel transcriptional target and mediator of mammary cell migration downstream of the Hippo pathway component TAZ.
Lai D, Yang X.
Cell Signal. 2013 Aug;25(8):1720-8. doi: 10.1016/j.cellsig.2013.05.002. Epub 2013 May 11.
PMID 23673366
 
Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: correlation with clinicopathological features and patients' prognosis.
Wei Z, Wang Y, Li Z, Yuan C, Zhang W, Wang D, Ye J, Jiang H, Wu Y, Cheng J.
J Oral Pathol Med. 2013 Nov;42(10):747-54. doi: 10.1111/jop.12062. Epub 2013 Mar 29.
PMID 23551691
 
TAZ expression as a prognostic indicator in colorectal cancer.
Yuen HF, McCrudden CM, Huang YH, Tham JM, Zhang X, Zeng Q, Zhang SD, Hong W.
PLoS One. 2013;8(1):e54211. doi: 10.1371/journal.pone.0054211. Epub 2013 Jan 23.
PMID 23372686
 
TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.
Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Patrizii M, Biffoni M, Maugeri-Sacca M, Piccolo S, De Maria R.
Oncogene. 2014 Feb 17. doi: 10.1038/onc.2014.5. [Epub ahead of print]
PMID 24531710
 
Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis.
Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE, Beede AM, Montoro DT, Sinkevicius KW, Walton ZE, Barrios J, Weiss DJ, Camargo FD, Wong KK, Kim CF.
EMBO J. 2014 Mar 3;33(5):468-81. doi: 10.1002/embj.201386082. Epub 2014 Feb 4.
PMID 24497554
 
The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment.
Skibinski A, Breindel JL, Prat A, Galvan P, Smith E, Rolfs A, Gupta PB, Labaer J, Kuperwasser C.
Cell Rep. 2014 Mar 27;6(6):1059-72. doi: 10.1016/j.celrep.2014.02.038. Epub 2014 Mar 6.
PMID 24613358
 
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written03-2014Yulei Zhao, Xiaolong Yang
Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada

Citation

This paper should be referenced as such :
Zhao Y, Yang X
WWTR1 (WW domain containing transcription regulator 1);
Atlas Genet Cytogenet Oncol Haematol. March 2014
Free online version   Free pdf version   [Bibliographic record ]
URL : http://AtlasGeneticsOncology.org/Genes/WWTR1ID44545ch3q25.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Jul 30 16:55:35 CEST 2014

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.